Publications by authors named "Anna So"
Article Synopsis
- - The study investigates how insulin resistance affects heart function in people with type 2 diabetes, comparing a well-known measure (HOMA-IR) to a more accurate method (hyperinsulinemic-euglycemic clamp analysis).
- - 34 individuals with type 2 diabetes were analyzed, finding that insulin sensitivity (ISI) was significantly connected to heart function measures, while HOMA-IR showed no correlation.
- - Results suggest that high insulin sensitivity is an important predictor of better heart function (measured by E/A ratio and LVEF), indicating a potential link between insulin resistance and heart problems in type 2 diabetes patients.
Sodium-glucose cotransporter 2 (SGLT2) inhibitors often increase the hematocrit. It remains unclear whether this increase would be observed in all patients administered SGLT2 inhibitors, however. We therefore used the data from the previous study and investigated time-dependent alterations of various outcomes related to erythrocytes, erythropoiesis, and clinical outcome in type 2 diabetes subjects ( = 89) treated with ipragliflozin for 16 weeks.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to compare the effects of two insulin types, insulin degludec (IDeg) and insulin glargine U300 (IGlarU300), on blood sugar stability in people with type 1 diabetes.
- In a crossover trial with 46 participants, each insulin was given for four weeks, and various glycaemic measurements were taken to evaluate their effectiveness.
- The results showed that both insulins had similar effects on blood sugar variability, but IDeg led to lower average blood sugar levels and better control compared to IGlarU300.
Article Synopsis
- The study aimed to evaluate if the homeostasis model assessment of insulin resistance (HOMA-IR) accurately reflects insulin sensitivity in patients with type 2 diabetes undergoing treatment with a sodium-glucose cotransporter 2 inhibitor (SGLT2i) like dapagliflozin.
- Researchers used hyperinsulinemic-euglycemic clamp analysis on 22 diabetic patients taking the medication and compared them with a matched control group of 44 patients not on SGLT2i, identifying 17 pairs for analysis.
- Results showed a negative correlation between natural log-transformed HOMA-IR and insulin sensitivity index (ISI) in both groups, but HOMA-IR values were lower for the SGLT
Article Synopsis
- The study investigates the effects of the SGLT-2 inhibitor ipragliflozin on appetite and weight loss in individuals with type 2 diabetes who have poorly controlled blood sugar levels.
- After 16 weeks of treatment, patients showed significant decreases in both blood sugar and body weight, but an increase in hunger was also observed.
- The findings suggest that while ipragliflozin helps with glycemic control and body weight reduction, it may also lower leptin levels (a hormone that suppresses appetite), potentially leading to increased appetite.
Aims: Evidence suggests that sensor augmented pump (SAP) therapy is superior to conventional continuous subcutaneous insulin infusion (CSII) for achieving glycemic control in patients with type 1 diabetes. However, the clinical benefit of SAP therapy in East Asians has not yet been demonstrated.
Methods: The effect of switching from conventional CSII to SAP therapy on glycemic profile was examined in 18 Japanese patients with type 1 diabetes.
Introduction: Administered basal insulin markedly influences the fasting plasma glucose (FPG) level of individuals with type 1 diabetes. Insulin degludec (IDeg) and insulin glargine U300 (IGlar U300) are now available as ultra-long-acting insulin formulations, but whether or how their glucose-stabilizing effects differ remains unclear. We will compare the effects of these basal insulins on parameters related to blood glucose control, with a focus on day-to-day glycemic variability, in individuals with type 1 diabetes treated with multiple daily injections.
View Article and Find Full Text PDFContext: Pheochromocytoma and paraganglioma are catecholamine-producing tumors that often impair glucose tolerance. The effects of these tumors on insulin sensitivity and insulin secretion in patients have remained unclear, however.
Objective: To characterize the influence of pheochromocytoma or paraganglioma on glucose tolerance, we comprehensively analyzed various parameters related to insulin secretion or insulin sensitivity in patients with these tumors.
The association between atherosclerosis and gut microbiota has been attracting increased attention. We previously demonstrated a possible link between gut microbiota and coronary artery disease. Our aim of this study was to clarify the gut microbiota profiles in coronary artery disease patients using data mining analysis of terminal restriction fragment length polymorphism (T-RFLP).
View Article and Find Full Text PDFAim: Recent studies have suggested that metabolic disorders such as obesity and type 2 diabetes are associated with gut microbiota. The association between atherosclerosis and gut microbiota has also been attracting increased attention. Our aim was to specify a characteristic trend of gut microbiota in coronary artery disease (CAD).
View Article and Find Full Text PDFAims/hypothesis: We compared the effects of insulin degludec (IDeg; Des(B30)LysB29(γ-Glu Nε-hexadecandioyl) human insulin) and insulin glargine (IGlar; A21Gly,B31Arg,B32Arg human insulin) on the day-to-day variability of fasting plasma glucose (FPG) levels in individuals with type 1 diabetes treated with basal-bolus insulin injections.
Methods: The effects of basal-bolus insulin therapy for 4 weeks with either IDeg or IGlar as the basal insulin in adult C-peptide-negative outpatients with type 1 diabetes were investigated in an open-label, multicentre, randomised, crossover trial. Randomisation was conducted using a centralised allocation process.